Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07177196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation
Trial Details
NCT Number NCT07177196
Lead Sponsor n-Lorem Foundation
Collaborators: University of California, San Diego
Conditions
(from sponsor)		 Retinal Dystrophy
Related terms Retinal Dystrophies
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov